Dacomitinib improves chemosensitivity of cisplatin-resistant human ovarian cancer cells

Drug resistance hinders effectiveness of human ovarian cancer (OC) therapies, such as cisplatin or paclitaxel therapy. Although dacomitinib, a novel anticancer agent is used against multiple types of cancers, such as non-small cell lung cancer, head and neck cancer, few studies report its effectiven...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Lei, Xu, Ying, Zheng, Jianbing, Zhao, Yun, Wang, Hongcai, Qi, Yushu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185702/
https://www.ncbi.nlm.nih.gov/pubmed/34113397
http://dx.doi.org/10.3892/ol.2021.12830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185702/
https://www.ncbi.nlm.nih.gov/pubmed/34113397
http://dx.doi.org/10.3892/ol.2021.12830

Ejemplares similares